Phase 3 · Liraglutide

NCT04775082 trial results

Last updated

Effect and Safety of Liraglutide 3.0 mg on Weight Management in Children With Obesity Aged 6 to Below 12 Years: 56-week, Double-blind, Randomised, Placebo-controlled Trial

Relative Change in Body Mass Index (BMI) (Percentage (%) change of BMI), Baseline (week 0), week 56. Liraglutide 3.0 mg: -6.7; Placebo: 2.1.

Participants
82
Status
active, not recruiting
Completed
2027-02-08
Sponsor
Novo Nordisk A/S

As posted on ClinicalTrials.gov (NCT04775082) (clinicaltrials.gov/study/NCT04775082), updated at source Nov 16, 2026. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.

Liraglutide: the lowest self-pay prices now

Primary outcome

What NCT04775082 measured first

Relative Change in Body Mass Index (BMI)Percentage (%) change of BMI · Baseline (week 0), week 56 · mean
Liraglutide 3.0 mgn=52Placebon=23
-6.7(9.6)2.1(6.1)

From the results posted on ClinicalTrials.gov (NCT04775082) (clinicaltrials.gov/study/NCT04775082), updated at source Nov 16, 2026.

Side effects by arm

Side effects in NCT04775082

Percent of participants affected, From baseline (week 0) to week 82. The most common events the registry lists.

EventLiraglutide 3.0 mgPlacebo
Any serious event12.5%7.7%
Vomiting62.5%15.4%
Nausea44.6%19.2%
Diarrhoea33.9%26.9%
COVID-1919.6%23.1%
Headache14.3%23.1%
Contusion7.1%19.2%
Pyrexia8.9%19.2%
Abdominal pain upper17.9%15.4%
Nasopharyngitis16.1%7.7%
Abdominal pain12.5%15.4%
Gastroenteritis14.3%7.7%
Upper respiratory tract infection14.3%11.5%
Asthma0%11.5%
Cough3.6%11.5%
Viral infection7.1%11.5%
Decreased appetite10.7%7.7%
Dyslipidaemia0%7.7%
Fatigue1.8%7.7%
Increased appetite3.6%7.7%
Influenza3.6%7.7%
Injection site bruising3.6%7.7%
Oropharyngeal pain1.8%7.7%
Pharyngitis1.8%7.7%
Respiratory tract infection viral1.8%7.7%
Tonsillitis0%7.7%

From the results posted on ClinicalTrials.gov (NCT04775082) (clinicaltrials.gov/study/NCT04775082), updated at source Nov 16, 2026.

Secondary outcomes

What else it measured

Relative Change in Body Weight (Percentage)Percentage (%) change of body weight · Baseline (week 0), week 56 · mean
Liraglutide 3.0 mgn=52Placebon=23
0.4(10.7)10.2(6.8)

From the results posted on ClinicalTrials.gov (NCT04775082) (clinicaltrials.gov/study/NCT04775082), updated at source Nov 16, 2026.

Percentage of Participants Achieving More Than or Equal to (≥) 5% Reduction of BMIPercentage (%) of participants · At week 56 · number
MeasureLiraglutide 3.0 mgn=52Placebon=23
Yes46.28.7
No53.891.3

From the results posted on ClinicalTrials.gov (NCT04775082) (clinicaltrials.gov/study/NCT04775082), updated at source Nov 16, 2026.

Change in Body Weight (Kilogram)Kilogram (kg) · Baseline (week 0), week 56 · mean
Liraglutide 3.0 mgn=52Placebon=23
0.1(8.2)7.5(5.3)

From the results posted on ClinicalTrials.gov (NCT04775082) (clinicaltrials.gov/study/NCT04775082), updated at source Nov 16, 2026.

Change in BMI Standard Deviation Score (WHO.Int)Z-score · Baseline (week 0), week 56 · mean
Liraglutide 3.0 mgn=52Placebon=23
-0.78(0.58)-0.34(0.33)

From the results posted on ClinicalTrials.gov (NCT04775082) (clinicaltrials.gov/study/NCT04775082), updated at source Nov 16, 2026.

Percentage of Participants Achieving ≥10% Reduction of BMIPercentage (%) of participants · At week 56 · number
MeasureLiraglutide 3.0 mgn=52Placebon=23
Yes34.64.3
No65.495.7

From the results posted on ClinicalTrials.gov (NCT04775082) (clinicaltrials.gov/study/NCT04775082), updated at source Nov 16, 2026.

Change in BMI Percentage of the 95th Percentile on Gender and Age-specific Growth Charts (CDC.Gov [CDC: {Centers for Disease Control and Prevention}])% change in BMI% of the 95th percentile · Baseline (week 0), week 56 · mean
Liraglutide 3.0 mgn=52Placebon=23
-15.1(12.9)-3.4(7.4)

From the results posted on ClinicalTrials.gov (NCT04775082) (clinicaltrials.gov/study/NCT04775082), updated at source Nov 16, 2026.

Change in Waist CircumferenceCentimeter (cm) · Baseline (week 0), week 56 · mean
Liraglutide 3.0 mgn=52Placebon=23
-1.89(8.34)3.06(7.74)

From the results posted on ClinicalTrials.gov (NCT04775082) (clinicaltrials.gov/study/NCT04775082), updated at source Nov 16, 2026.

Change in Systolic Blood PressureMillimeters of mercury (mmHg) · Baseline (week 0), week 56 · mean
Liraglutide 3.0 mgn=52Placebon=23
-2(10)0(13)

From the results posted on ClinicalTrials.gov (NCT04775082) (clinicaltrials.gov/study/NCT04775082), updated at source Nov 16, 2026.

Change in Diastolic Blood PressuremmHg · Baseline (week 0), week 56 · mean
Liraglutide 3.0 mgn=52Placebon=23
-1(10)0(10)

From the results posted on ClinicalTrials.gov (NCT04775082) (clinicaltrials.gov/study/NCT04775082), updated at source Nov 16, 2026.

Change in Glycated Haemoglobin (HbA1c)Percentage change in HbA1c · Baseline (week 0), week 56 · mean
Liraglutide 3.0 mgn=51Placebon=23
-0.2(0.2)0.0(0.2)

From the results posted on ClinicalTrials.gov (NCT04775082) (clinicaltrials.gov/study/NCT04775082), updated at source Nov 16, 2026.

Treatment Emergent Adverse Events (TEAEs)Number of events · From baseline (week 0) to week 82 · number
Liraglutide 3.0 mgn=56Placebon=26
436156

From the results posted on ClinicalTrials.gov (NCT04775082) (clinicaltrials.gov/study/NCT04775082), updated at source Nov 16, 2026.

Treatment Emergent Serious Adverse Events (SAEs)Number of events · From baseline (week 0) to week 82 · number
Liraglutide 3.0 mgn=56Placebon=26
122

From the results posted on ClinicalTrials.gov (NCT04775082) (clinicaltrials.gov/study/NCT04775082), updated at source Nov 16, 2026.

The trial

How NCT04775082 was run

The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects. Participants will either get liraglutide or placebo. Which treatment the participants get is decided by chance. Liraglutide is a new medicine for children, but it can already be prescribed by doctors to adults with overweight or obesity. The participant will get 1 injection every day. In addition to taking the medicine, the participants will have talks with the study staff about healthy food choices, how they can be more physically active and what can be done to help the participants to lose weight. The study will last for about 96 weeks (almost 2 years). The participants will have 18 clinic visits and 10 phone or video calls with the study doctor/staff. Participant will have blood samples taken, have 1 test to check the heart, 1 hand X-ray taken and must fill in a diary between some of the visits.

  • Liraglutide 3.0 mg: The treatment duration is 56 weeks and the follow-up period is 26 weeks.
  • Placebo: The treatment duration is 56 weeks and the follow-up period is 26 weeks.
Who could join the trial

Inclusion Criteria: * Informed consent of parent(s) or legally acceptable representative of subject and child assent, as age-appropriate, obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial * Male or female, aged 6 to below 12 years at the time of signing informed consent * Tanner stage 1-5 pubertal development at the time of signing informed consent * BMI above or equal to 95th percentile, on gender and age-specific growth charts (CDC.gov) * History of failing to lose sufficient weight with lifestyle modification as judged by the investigator For subjects with type 2 diabetes at screening the following inclusion criterion apply in addition: \- Hemoglobin A1c (HbA1c) below or equal to 10.0 percent (86 mmol/mol) as measured by central laboratory at screening Exclusion Criteria: * A self-reported (or by parent(s)/LAR (legally acceptable representative) where applicable) change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records * Treatment with any medication for the indication of obesity within the past 90 days before screening * Type 1 diabetes * Subjects with secondary causes of obesity (for example hypothalamic, monogenic or endocrine causes)

In the trial's own words, from its record on ClinicalTrials.gov (NCT04775082) (clinicaltrials.gov/study/NCT04775082), updated at source Nov 16, 2026.

Published papers

Papers from NCT04775082

  • Fox CK, Barrientos-Perez M, Bomberg EM, Dcruz J, Gies I, Harder-Lauridsen NM, Jalaludin MY, Sahu K, Weimers P, Zueger T, Arslanian S; SCALE Kids Trial Group. Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial. N Engl J Med. 2025 Feb 6;392(6):555-565. doi: 10.1056/NEJMoa2407379. Epub 2024 Sep 10. (pubmed.ncbi.nlm.nih.gov/39258838)

Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.